Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.
Werewolf Therapeutics Stock Down 0.8 %
Werewolf Therapeutics stock traded down $0.01 during trading on Friday, reaching $1.20. 251,631 shares of the company's stock were exchanged, compared to its average volume of 270,648. The company's 50-day moving average is $1.35 and its two-hundred day moving average is $1.80. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics has a 52-week low of $1.03 and a 52-week high of $6.89. The firm has a market cap of $53.48 million, a price-to-earnings ratio of -0.78 and a beta of 0.37.
Analysts Set New Price Targets
Several analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday. Wedbush reissued an "outperform" rating and set a $8.00 price objective on shares of Werewolf Therapeutics in a research note on Wednesday. Finally, JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research note on Tuesday, January 14th.
Read Our Latest Stock Report on Werewolf Therapeutics
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
See Also
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
